How Pharma Is Outsourcing Oncology Target Discovery in 2026

On April 9, 2026, Oxford BioTherapeutics announced a multi-year collaboration with Bristol Myers Squibb focused on the discovery and development of T-cell engager therapies for solid tumors.1 According to the agreement, Oxford BioTherapeutics will use its OGAP-Verify platform to find specific targets in solid cancers and create new T-cell engager molecules. Bristol Myers Squibb will then lead subsequent research, development, and commercialization activities.

The deal places target identification and the generation of development candidates within Oxford BioTherapeutics before handoff to Bristol Myers Squibb for the later-stage work.1 That division of labor reflects a new industry trend that is shifting toward more modular collaboration models, in which specialized platform technologies are brought in at the discovery and preclinical stages rather than developed in-house.

What Does the OGAP-Verify Platform Contribute?

The OGAP-Verify platform is designed for highly sensitive identification of oncology targets with attributes that support downstream drug development, with a particular emphasis on tumor selectivity.1 Oxford BioTherapeutics' remit extends beyond target identification to include the design and delivery of development candidates, a scope that signals the platform's positioning as less of a discovery tool than a preclinical development tool.

"This new partnership builds on the proven strength of our platform to identify and validate highly differentiated, tumor-selective targets and reflects the growing confidence in our ability to translate that science into development-ready therapeutic candidates," said Christian Rohlff, chief executive officer, Oxford BioTherapeutics, in a press release.1

T-cell engagers for solid tumors remain a challenging area of oncology drug development.1 Unlike hematological malignancies, solid tumors present significant obstacles around target accessibility, tumor microenvironment immunosuppression, and on-target off-tumor toxicity. The emphasis on tumor-selective targets in this collaboration speaks directly to those challenges.

Why Does the Timing of This Deal Matter for the Broader Field?

This agreement is the third major pharmaceutical collaboration Oxford BioTherapeutics has entered in the past twelve months, following partnerships with GSK and Roche in 2025.1 The pace these deals are being drafted suggests that large pharmaceutical companies are actively seeking external platform capabilities for oncology target discovery rather than relying solely on internal research infrastructure.

"Collaborating with Bristol Myers Squibb, a global leader in oncology, represents an important milestone for OBT and underscores the momentum behind our partnerships with leading pharmaceutical companies," said Rohlff, in the press release.1 "By combining OGAP-Verify's discovery and validation capabilities with Bristol Myers Squibb's expertise in translating oncology innovation into clinical and commercial outcomes, we are confident that together we can advance a new generation of innovative cancer therapies that have the potential to make a meaningful difference for patients."

Deals at this stage are often early signals of what assets may eventually require scale-up and manufacturing support.1 Biologics-based T-cell engagers, including bispecific formats, carry well-documented complexity in terms of expression systems, purification, and formulation. Monitoring which targets and molecular formats emerge from collaborations like this one can inform capacity planning and technology readiness well ahead of late-stage development timelines.

How Else Is BMS Approaching the Cancer Care Pathway?

The T-cell engager collaboration with Oxford BioTherapeutics sits at the discovery end of oncology drug development, but Bristol Myers Squibb is also investing in infrastructure that shapes the detection of cancer.2 A separate agreement with Microsoft aims to accelerate early detection of lung cancer by deploying AI radiology algorithms through Microsoft's imaging network. The system is designed to help detect surface lung nodules that might otherwise go unnoticed, and to track patients with incidental findings through follow-up care pathways. This is an area where current loss-to-follow-up rates exceed 50%. The signal is clear, that Bristol Myers Squibb is investing in its oncology pipeline at multiple levels, they are looking to cover novel target identification through to the point of diagnosis.

References

1. Oxford BioTherapeutics. Oxford BioTherapeutics Enters Strategic Collaboration with Bristol Myers Squibb to Discover and Develop Next-Generation T-cell Engagers for Solid Tumours. Oxford BioTherapeutics; April 9, 2026. https://oxford-biotherapeutics.lon1.cdn.digitaloceanspaces.com/OBT-BMS-2026-04-09.pdf
2. Bristol Myers Squibb. Bristol Myers Squibb announces collaboration with Microsoft to advance AI-driven early detection of lung cancer. Bristol Myers Squibb. Published January 19, 2026. https://news.bms.com/news/corporate-financial/2026/Bristol-Myers-Squibb-Announces-Collaboration-with-Microsoft-to-Advance-AI-Driven-Early-Detection-of-Lung-Cancer/default.aspx